Family genetic risk communication and reverse cascade testing in the BabySeq project
- PMID: 39731470
- PMCID: PMC12264819
- DOI: 10.1016/j.gim.2024.101350
Family genetic risk communication and reverse cascade testing in the BabySeq project
Abstract
Purpose: Genomic sequencing of newborns can initiate disease surveillance and therapy for children and may identify at-risk relatives through reverse cascade testing. We explored genetic risk communication and reverse cascade testing among families of newborns who underwent exome sequencing and were identified as having a risk for an autosomal dominant disease.
Methods: We conducted semistructured interviews with parents of newborns enrolled in the BabySeq Project who had a pathogenic or likely pathogenic variant associated with an autosomal dominant childhood- and/or adult-onset disease returned. We used directed content analysis to derive themes.
Results: From 11 families, all first-degree relatives (n = 32, 100%), 29 second-degree relatives (76%), and 26 third-degree relatives (43%) were informed of their risk. All parents (n = 22, 69% of first-degree relatives), 4 (11%) second-degree relatives, and 1 (2%) third-degree relatives underwent cascade testing. Most parents preferred to handle risk communication themselves. Parents with positive cascade testing but no associated symptoms were less inclined to share findings with relatives but highly motivated to share results if the variant's associated disease severity was high, as perceived with adult-onset conditions. One new subtheme, family member traits, was identified and defined as a relative's propensity to anxiety/concern after risk communications but did not diminish risk communication.
Conclusion: Findings can inform more effective notification and testing practices for families of newborns at risk for hereditary genetic conditions.
Keywords: Cascade testing; Genetic risk communication; Pediatrics; Qualitative research.
Copyright © 2024 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Alan H. Beggs has received funding from the National Institutes of Health, Muscular Dystrophy Association (USA), Alexion Pharmaceuticals Inc, Audentes Therapeutics Inc, Dynacure SAS, and Pfizer Inc; has consulted and received compensation or honoraria from Audentes Therapeutics, Biogen, F. Hoffman-LaRoche AG, GLG Inc, Guidepoint Global LLC, and Kate Therapeutics Inc; and holds equity in Kinea Bio and Kate Therapeutics Inc. Robert C. Green is an advisor for AIA, SavvySherpa, Verily, and Wamberg Genomic Advisors and cofounder of Genome Medical, Inc. Amy L. McGuire is a consultant for Geisinger Research, the Greenwall Foundation, Morgridge Institute for Research, and Danaher Life Sciences. Hadley Stevens Smith has received consulting income from Illumina, Inc, unrelated to this work. All other authors declare no conflicts of interest.
References
-
- Nurchis MC, Riccardi MT, Radio FC, et al. Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence. Health Policy. 2022;126(4):337–345. doi: 10.1016/j.healthpol.2022.03.001 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
